Multicentric non-interventional prospective study assessing antiemetic guidelines consistency in chemotherapy-induced nausea and vomiting (CINV) prophylaxis and the impact of CINV on the quality of life on cancer patients receiving moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC).
start of the project: October 2016
end of the project: March 2020
As patients still consider CINV as one of the most distressing side effects of chemotherapy, the potential to improve patient´s quality of life is still there. The best suited supportive care to the patient can improve not only the quality of life of the patient, but also, in long term, the response to anticancer treatment and patients´ survival. Initiation of such a registry could also increase the awareness and experience of supportive care in cancer patients by oncologists and nurses.
Primary objective of the project:
Secondary objectives of the project:
Other important information: